Discounted Cash Flow (DCF) Analysis Levered

AVEO Pharmaceuticals, Inc. (AVEO)

$15

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: -21,565.36 | 15 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 7.585.4128.796.0238.87123.47392.171,245.613,956.3112,566.01
Revenue (%)
Operating Cash Flow -19.16-25.03-2.92-37.98-57.26-371.40-1,179.65-3,746.81-11,900.63-37,798.76
Operating Cash Flow (%)
Capital Expenditure ----0.36-2.34-7.45-23.65-75.12-238.60-757.84
Capital Expenditure (%)
Free Cash Flow -19.16-25.03-2.92-38.35-59.60-378.85-1,203.31-3,821.94-12,139.23-38,556.60

Weighted Average Cost Of Capital

Share price $ 15
Beta 0.977
Diluted Shares Outstanding 21.40
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.255
Total Debt -
Total Equity 321.03
Total Capital 321.03
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 7.585.4128.796.0238.87123.47392.171,245.613,956.3112,566.01
Operating Cash Flow -19.16-25.03-2.92-37.98-57.26-371.40-1,179.65-3,746.81-11,900.63-37,798.76
Capital Expenditure ----0.36-2.34-7.45-23.65-75.12-238.60-757.84
Free Cash Flow -19.16-25.03-2.92-38.35-59.60-378.85-1,203.31-3,821.94-12,139.23-38,556.60
WACC
PV LFCF -349.95-1,026.69-3,012.17-8,837.29-25,927.38
SUM PV LFCF -39,153.47

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.26
Free cash flow (t + 1) -39,327.73
Terminal Value -628,238.53
Present Value of Terminal Value -422,458.89

Intrinsic Value

Enterprise Value -461,612.36
Net Debt -70.54
Equity Value -461,541.82
Shares Outstanding 21.40
Equity Value Per Share -21,565.36